202 related articles for article (PubMed ID: 31540560)
1. Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock.
Coleman PJ; Nissen AP; Kim DE; Ainsworth CR; McCurdy MT; Mazzeffi MA; Chow JH
Semin Cardiothorac Vasc Anesth; 2020 Sep; 24(3):266-272. PubMed ID: 31540560
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II in septic shock.
Jadhav AP; Sadaka FG
Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II in Refractory Septic Shock.
Antonucci E; Gleeson PJ; Annoni F; Agosta S; Orlando S; Taccone FS; Velissaris D; Scolletta S
Shock; 2017 May; 47(5):560-566. PubMed ID: 27879559
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.
Chow JH; Wallis M; Lankford AS; Chancer Z; Barth RN; Scalea JR; LaMattina JC; Mazzeffi MA; McCurdy MT
Semin Cardiothorac Vasc Anesth; 2021 Mar; 25(1):67-73. PubMed ID: 32787515
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II in Vasodilatory Shock.
Wakefield BJ; Busse LW; Khanna AK
Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia.
Bui AD; Helgeson SA; Guru PK; Sanghavi DK
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32595128
[TBL] [Abstract][Full Text] [Related]
8. THE ROLE OF ANGIOTENSIN -2 IN THE PATHOGENESIS OF SEPTIC SHOCK DURING MULTIORGAN DYSFUNCTION SYNDROME (REVIEW).
Rurua M; Machavariani K; Sanikidze T; Shoshiashvili V; Pachkoria E; Ratiani L
Georgian Med News; 2022 Feb; (323):157-161. PubMed ID: 35271489
[TBL] [Abstract][Full Text] [Related]
9. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
[TBL] [Abstract][Full Text] [Related]
10. Vasodilatory shock in the ICU and the role of angiotensin II.
Wakefield BJ; Sacha GL; Khanna AK
Curr Opin Crit Care; 2018 Aug; 24(4):277-285. PubMed ID: 29877879
[TBL] [Abstract][Full Text] [Related]
11. The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
Teixeira JP; Perez Ingles D; Barton JB; Dean JT; Garcia P; Kunkel SJ; Sarangarm P; Weiss NK; Schaich CL; Busse LW; Nielsen ND
Trials; 2024 Mar; 25(1):182. PubMed ID: 38475822
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management.
Senatore F; Balakumar P; Jagadeesh G
Pharmacol Res; 2021 Dec; 174():105916. PubMed ID: 34597810
[TBL] [Abstract][Full Text] [Related]
13. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
[TBL] [Abstract][Full Text] [Related]
14. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II for the Treatment of Vasodilatory Shock.
Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
[TBL] [Abstract][Full Text] [Related]
16. The ATHOS-3 trial, angiotensin II and The Three Musketeers.
Bellomo R; Hilton A
Crit Care Resusc; 2017 Mar; 19(1):3-4. PubMed ID: 28215124
[No Abstract] [Full Text] [Related]
17. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin for septic shock unresponsive to noradrenaline.
Yunge M; Petros A
Arch Dis Child; 2000 May; 82(5):388-9. PubMed ID: 10799431
[TBL] [Abstract][Full Text] [Related]
19. Role of angiotensin II in treatment of refractory distributive shock.
Rodriguez R; Fernandez EM
Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
[TBL] [Abstract][Full Text] [Related]
20. Severe septic shock unresponsive to noradrenaline.
Wray GM; Coakley JH
Lancet; 1995 Dec; 346(8990):1604. PubMed ID: 7500755
[No Abstract] [Full Text] [Related]
[Next] [New Search]
